Read time: 7 minutes
After a slow start, biosimilar adoption rates are trending upward in the United States. According to AmGen, there was a 65% increase in the number of approved biosimilars between 2019-2020 and a 157% increase in available biosimilars in the U.S.
An expert from our 340B Solutions team explains what these biosimilar adoption rates mean for 340B-qualified pharmacies.
Learn more about navigating the use of biosimilars with the 340B Drug Pricing Program.
Share
Post
Post
Email